Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tysabri

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

- PMLiVE

NICE recommends infliximab biosimilars ahead of Remicade

Newly-acquired Hospira and Napp see their infliximab products backed by the HTA body

Biogen promotes Matt Griffiths to chief information officer

He originally joined the firm from Dell earlier this year

- PMLiVE

Genzyme and Ablynx collaborate on multiple sclerosis research

Companies will investigate Nanobodies against MS target

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Remicade biosimilars hit European market

Hospira and Mundipharma begin marketing their version of the blockbuster drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links